After the interest received by the previous editions and the excellent feed-back from all the attendants, the 11th edition of the ACT course will be organized by the ESACT (European Society of Animal Cell Technology) again in 2021. ESACT is presenting this activity as one more contribution to the community involved in the use of animal cells in Biotechnology and Biomedicine. ESACT is proud to announce the recognition of the ACT ESACT course by ACTIP – the Animal Cell Technology Industrial Platform – that will sponsor the course with a limited number of grants to cover registration fees.

A limited number of grants, covering the course fee are provided by ESACT. Applicants to the grants should indicate it in the course application, together with a motivation statement. Priority will be given to young PhD students from Academia. The course comprises lectures covering the main topics of Animal Cell Technology:

• Cell line development
• Cellular mechanisms
• Genomics and proteomics
• Post-translational modifications
• Bioreactor scale-up, scale down and single use bioreactor
• Downstream processing
• Integrated bioprocess for cell based vaccines
• Economical aspects of ACT bioprocesses
• Integrated bioprocess for protein production
• Integrated bioprocess for stem cells
• Industrial perspectives of ACT

The program has slots dedicated to the preparation and presentation of case studies by participants, and discussion groups with the lecturers.

Inquired speakers: Terry Papoutsakis (University Delaware, USA), Manuel Carrondo and Paula Alves (iBET, Portugal), Hansjörg Hauser (HZI, Germany), Francesc Gòdia (UAB, Spain), Stefanos Grammatikos (UCB Pharma SA, Belgium) and Anne Tolstrup (Biogen, Denmark).

download flyer with detailed information → (coming soon)